Liz Parrish CEO of BioViva/Patient ZERO: A Fighter for the Reversal of Biological Aging [Part 2]

Click here for Part 1

Published on Oct 31, 2015

“We treat aging as a disease. It’s the number one killer in industrialized countries. Biological aging underlies the disease we get.” – Liz Parish

• Patient zero indicates that she is the first person to undergo gene therapy to reverse aging.
• Myostatin inhibitors is proven and tested. There have been many human and animal trials already for this therapy.
• She is the first to undergo Telemore induction and explains that they aren’t sure what will happen to her in several decades from now. But her team wants to find out.
• Liz explains that she hopes that these technologies are available to the mass public as soon as possible. Many companies are already developing their own version based on her treatment. Public support and awareness will be key to allowing these technologically superior treatments to become more widespread in usage.
• They are interested in seeing how these therapies will affect the offspring of those that have had their genes edited.

Liz’s response to why many people do not know about anti-aging research and longevity research:

“Well I think that its a multi-prompted issue… for one thing anti-aging has definitely been you know… the first person to come to it didn’t have much to sell lets just say. Right? The best thing you can do for the average person right now is to exercise and good nutrition. Don’t over eat and exercise your body. We do know that phenotypically, you know genetically, epigenetically, we change many genes by doing that. Thats going to put you at your best youngest state. Don’t smoke cigarettes thats number one. Outside of that there hasn’t been that much to offer. We’ve done things like nip and tucks and injecting faces you know with plastic and various things and I understand why people do it. Especially being someone getting older you become more and more invisible you know as you get older… so but there was nothing really to offer to fix. And so when human growth hormone came along, you saw how many people jumped on that bandwagon. You know there’s evidence that that is not the way to go it’s a short-term fix… but now people are going for quality instead of quantity. We want them to think about both of those things, we want them to think about quantity and quality together. We want people to reconsider leaving their legacy to universities and such like that and consider living their legacy. You know definitely put your money to research and medicine but live your legacy. See the fruits of your labor rather than thinking you need to die and leave everything behind to an institute that you received lots of benefits from. Its kind of like changing the mindset and it’s getting the real science out there. You know what’s actually happening at these levels. We’ve reversed aging in animals. We’ve done that. So why aren’t we doing that to humans? I think then you would have to go from that too what are the markets? You know our markets is through medical doctors and pharmaceuticals. You know pharmaceuticals are still an experiment. The FDA would say that they’re not experimental once they pass through the FDA – but their still an experiment and people are dying taking them. As a matter of fact you’re guaranteed to die from the disease that you are taking the drugs for. So a lot of people make a determination of whether the side effects are worth the benefit of their drugs often. And I’m not saying do not take your medicine, you should definitely should do what is prescribed by your doctor… but a lot of these doctors are unaware of new technology. I think that the big companies need to make a paradigm shift and we’re seeing that. We’re seeing more and more pharmaceutical companies get interested in the aspects of slowing down or reversing biological aging. And they really control the media… we have to admit it. When we came out with our release of this information, you know, we weren’t invited too all the big places right? Think about it. Even though one of the big things we can do as people in the world is cure disease, but you know you have to be really well connected and I think we will eventually make those connections. We’ll see. Were a good group, we are an honest group, and we’re really doing the work. How do you earn that credibility when you are not these larger companies?”

Liz believes the two best ways to make these technologies available to the public is:

1. Start a grassroots movement
2. Funding

• In regards to the notion that such therapies would only be available to the rich, Liz proposed that big companies would desire a longer living and healthier workforce. She pledges that BioViva would not let only the rich have access and reaffirms her organizations desire to make this available to the entire world.
• BioViva is unique because they are a small company that is not run by numbers, bureaucracy, and paperwork. No interest in stock market therefore no need to appease shareholders. Prefers to seek public money over government. Wants to be very transparent to the public.

Dated Nov 21, 2015

• Liz Parrish was drawn to the biotechnology world due to a family illness. She was in a hospital for her son who had diabetes and remembers wondering why there were children in the hospital dying of diseases, instead of having access to next generation therapies and treatments. Shes asked doctors there and was told that such technologies are “experimental and still in research.” Her curiosity to see the real truth of why such technologies were still unavailable to most of the public, drew her to a SENS conference.
• Mentions there are certain dosages that she can take. Implies that an increase in dosage can increase the effects.
• Catching the Flu indicates that new genes did not “stick.” Thus is the worst case scenario. High immune response can cause the gene therapy to not work.
• Notices post-therapy that she is experiencing deeper sleep. She is sleeping earlier at 7pm. Wakes up at 7am and feels refreshed. Has had no need or desire for caffeine.
• Her dreams have been more vivid and goes “all over the place.” Has noticed more brief awakenings which transpires when shes is coming out of a dream. During her brief awakenings, she feel completely awake, and then goes back to sleep.
• Has increased exercise, with an emphasis on weightlifting in order to the study her bodies output. Her muscles are less sore after workouts. Recovery from exercise has been “super fast.” While racing a friend, she felt muscle fibers that haven’t ached in a while, but by the next day, the aches disappears.
• Intended to not tell the media for a year. Wanted to study the data first an confirm successful results. She chose to be the first patient for her companies because she felt compelled to truly lead and represent her company and be the spokesperson. Wants build boards promoting these therapies.

What differentiates BioViva from other companies:

“Thats the great thing about a company like BioViva, is that, because were small, were able to do such things the bigger companies just can’t do. We’re able to help people quickly, we’re able to mobilize and we’re able to take great leaps in science because we don’t have a bureaucracy. Its so important the people get behind small biotechs because the monsters of the companies that are out there, the big monsters, is a slow go. And you see that. A lot Investors are not interested in putting money in biotech anymore because its a billion dollars that have to go through the FDA. And its very likely that their drug will never come to market. For various reasons. You can cure ten people, but if a hundred people have no effect, than nothing is going to come of that drug. But what about the ten people it killed? What about the ten people exponentially across the Earth, in humans and animals, of persons of a hundred thousand that it would help and cure? We have got to do the busy work, we have got to care about the ten people. (it cured)”

• Gene therapy can help improve stem cell signaling.
• Opted for two gene therapy because they know you need to modify more than one gene to successfully cure aging.
• Their proprietary blend is “extremely powerful and goes hand in hand.”
• Will be studying telomere length, methylation, (regulation of gene expression, regulation of protein function, and RNA processing), physical bio-markers, such as increased muscle mass, changes in tissue, blood work to observe increases in organ function and increase insulin sensitivity.
• Clarifies that she is not the first to do the myostatin inhibitor therapy (A doctor named Jason Williams was patient ZERO for that particular type of therapy), she is the first to do two gene therapies and is definitely the first publicly announced that she is the first to use the telomere induction therapy.
• Looking to start clinical trials in Mexico. Will help reduce costs, prove the science for patients in diseased states, and is a close distance from the USA.
• Believes the technology will change the world for the better and be massively profitable.
• Liz was a painter before starting BioViva.
• Wants to inspire more women to be involved in the biotech world, wants more women to make history, and seek more ambitious goals that can positively influence the entire human population.

Published on Jan 22, 2016

• Approximately 4 months after therapy.
• There are no negative side effects of these therapies. She mentions that she would not have taken these therapies if there were side effects.
• The Therapy was administered in South America (Columbia) at a medical clinic under the supervision of doctors and medical support teams. Due to the respect of their privacy, she has not disclosed the personal info of the doctors and medical staff. She believes their reputation will grow “beautifully”.
• The myostatin inhibitor has been tested in many animal models including primates. Currently the myostatin inhibitor is undergoing clinical trials in humans to treat muscular dystrophy. A medical doctor that works for BioViva personally took the therapy five years ago.
• Telemore induction has been tested in mice. Two major mice studies were conducted by Ron DePinho (Harvard Medical School) and Maria Blasco (Spanish National Cancer Research Centre). Before being used directly on humans, the technique was tested in human cell tissue.
• DePinho Telomere study
• Blasco Telemore study
• How did telemore induction effect mice? According to Liz the mice experienced age reversal- the size of the brain increased, old brains became youthful brains, and everything inside and outside the mice improved.
• Her company is focused on disease mitigation and solving childhood disease.
• BioViva has developed their own protocol for studying the effects of the duel gene therapy on Liz. They collect pre-therapy blood samples, tissue samples, blood tests, and MRIs and are looking to compare all the data post therapy.
• They are very intrigued by the biomarkers for her telomere length. Two other companies are also studying her telemore length. They collect data on her organ function, analyze whether her cells look and act youthfully, and MRIs studying her muscle mass. Will continue to collect data for the next eighteen months and perhaps for the rest of her life. Harvard is conducting their own review on the data collected and Liz calls forth all other major institutions to step forwards to do their own review of the data.

“I suffer from biological aging as a disease.” – Liz Parish

• Liz mentions they can detect early signs of Alzheimer’s, plaque, and cancer in people in their early twenties. Diseases that will kill people later in their life, start to develop early in their lives. There is a 80% likelihood of cancer after the age of sixty-five. Personally, since the age of thirty, Liz’s was losing 1% of her muscle mass every year. Therefore it is important to treat aging as early as possible.
• According to Liz, terminally ill patients should have the right to access these therapeutics, and believes her company should have the right to give these therapies to any terminally ill patient living in the US. Red-tape and the regulation is the reason the terminally ill do not have access to these therapies in our country. Wants to expedite good work. Wants patients to have the a choice on how they will be treated.

“This risk can create a healthier world and with one of the therapies never being used in humans before… We felt that it was an ethical issue and that we were the first company that took the first chance and saw what happened.”

• One-hundred thousand people die of aging related illness every day. Recently lost David Bowie, Alan Rickman, and Lemmy from Motorhead to aging disease!

“This is a mandate to rush to the future. This is a future for everyone. The minute we can cure aging, we should be doing that!”

• Liz explains that Telemore Lengthening Gene Therapy and Myostatin Inhibitors are the most powerful treatments available to beat biological aging. Both therapies were conducted together with the goal of complimenting each other and optimizing each others effects.
• The best case scenario: Reversal of aging. Worst case: No result.
• Liz studied “death” for two years and claims to knows how she will die. She has done presentations on the study of death by the numbers, such as how people died in 1665. She studied how many people die from cancer, heart disease, kidney failure, diabetes type2, and Alzheimer’s. Since these are the most common major diseases, her logic is that she would have died from one of these listed illnesses. After undergoing her therapies, she proclaims that she does not know how she will die anymore.

“I know I was going to die if I didn’t do it. I wasn’t going to take the status quo… so I don’t have the same fears and worries that other people do. And I hope that people understand that this is my human right to do.

“When I came home I wrote down into a transcript that I’m turning into my diary and of things that are going on. I wrote down that, ‘If you can do an action that might save a thousand people, or a million people, or a billion people, but you might die from doing it, would you do it?’ And then I wrote, ‘I would!’ And I did! And I am going to tell you my story!”

“I just feel very strongly that we need to pioneer new medicine. We cannot wait for these slow route, money making machine companies that have had no incentive to cure disease. You know? Thats not their business. We need business that cures disease.”

• Her personal analysis of the results from the therapy: Feels great, sleeping well, feeling stronger, and has more muscle mass. Bodybuilders say that she has more muscle mass than she should at the age of 45. This is factoring in that she does not take testosterone or growth hormones. Has been an avid runner and exerciser for years. Noticed an increase in weight and a decrease around her waist. Lost an inch on her waist but got heavier because muscle is denser.
• They have started gene therapy trials offshore. This allows them to run their operations at the fraction of the cost.
• Once the technology is deemed completely safe, they are looking to give these therapies to younger and younger people within twenty to thirty years so that young people can never get sick. Wants to see if the offspring of the patients will be effected. Wants to also study the effects on the forty and fifty years old age group. She believes that the technology will even work on sixty year olds.
• Seeking to create a framework that can provide guidance to young entrepreneurs desiring to create their own biotechnology companies.
• These therapies cost about hundreds of thousands of dollars. ($250,000 is a number I saw) Wants the cost of these therapies to become affordable. Needs investments. The reason they are expensive is that they need to customize the therapies for each individual person, its very specialized procedure, and its a very gradual process that takes weeks or months to “get the therapy.” Other companies are looking to charge millions of dollars for a treatment after FDA approval. Her team is looking to get the cost half or even a quarter of that amount and less expensive after that.
• Within 5-7 years she believes that the cost can get around $10,000 dollars or less. At that price point, insurance companies will definitely want to cover it because then these insurance companies will get to spend less on patients. (Just think, In the future, if nobody gets sick anymore, then what would be the purpose of insurance? Whats the point of forking money over to insurance companies when they will never have a reason to compensate you for an illness. If anything this type of technology should make insurance companies completely obsolete)
• Seems to support the transhumanist movement. Has met Zoltan Istvan the political candidate for the transhumanist party who wants to make curing of death and aging a national priority. Supports the transhumanist movements notion of utilizing technologies to make humans stronger, faster, better, younger, and longer living.

BioViva does not perform gene editing on embryos. Although she has some powerful words relating to this sensitive subject:

“If there is a known gene that causes a disease, that's costly, takes away from that humans life, and we know that editing that gene out and replacing that with a good copy would help – we should – thats a mandate. Why would we bring sick children into the world? I don’t understand that. We do so many things under the guise of ethics… that are not ethical at all. You know? We let people die every single day that should be taking a therapeutic and trying a therapy, a gene therapy, a molecule, anything to save their lives! And yet we consider it more ethical to let them die. And were actually condemning these children, these embryos to a future of to sickle cell anemia, hemophilia, and various other things, that will in fact be curable disease in the very near future. They should be cured before these children are born.”

• Supports CRISPR gene editing technology. Wants to use all types of gene editing techniques to cure all disease at every level. Patents and licensing does not allow BioViva to use such type of technology at the moment and believes her companies has the right to access these technologies. Instead of fighting over usage, patents, and licensing, the goal should be to help the entire world by curing all disease and make an everlasting impact in human history for all time and the creation unlimited time.
• BioViva Website for updates on Liz